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The peripheral nervous system and the pathogenesis of prion
diseases
Abstract
Prion diseases are inevitably fatal neurodegenerative conditions which affect humans and a wide variety
of animals. Unlike other protein aggregation diseases such as Alzheimer's, Parkinson's, and
polyglutamine repeat diseases, prion diseases are unique in that they are transmissible. Therefore, prion
diseases are also called transmissible spongiform encephalopathies. A number of prion diseases are
caused by peripheral uptake of the infectious agent. In order to reach their target, the central nervous
system, prions enter their host, accumulate and replicate in lymphoid organs, and eventually spread to
the central nervous system via peripheral nerves. Once the agent has reached the central nervous system,
disease progression is rapid, resulting in neurodegeneration and death. In this article, we review the state
of knowledge on the routes of neuroinvasion used by the infectious agent in order to gain access to the
central nervous system upon entry into extracerebral sites.
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Abstract: Prion diseases are inevitably fatal neurodegenerative conditions which affect humans and a
wide variety of animals. Unlike other protein aggregation diseases such as Alzheimer’s, Parkinson’s,
and polyglutamine repeat diseases, prion diseases are unique in that they are transmissible.
Therefore, prion diseases are also called transmissible spongiform encephalopathies.
A number of prion diseases are caused by peripheral uptake of the infectious agent. In order to reach
their target, the central nervous system, prions enter their host, accumulate and replicate in lymphoid
organs, and eventually spread to the central nervous system via peripheral nerves. Once the agent
has reached the central nervous system, disease progression is rapid, resulting in neurodegeneration
and death. In this article, we review the state of knowledge on the routes of neuroinvasion used by
the infectious agent in order to gain access to the central nervous system upon entry into
extracerebral sites.
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INTRODUCTION
Prion diseases, or transmissible spongiform
encephalopathies (TSEs), are neurological disorders
caused by transmissible pathogens termed prions
[1]. According to available evidence, prions are
devoid of informational nucleic acids and consist of
an “infectious” protein capable of converting a
normal host protein called PrPC into a pathogenic
isoform of itself termed PrPSc [2].
Prion diseases occur both in humans and in
animals. In animals, diseases such as scrapie of
sheep have been known to exist for centuries.
Newer examples of prion diseases occurring in
animals are the bovine spongiform encephalopathy
(BSE) [3], or “mad cow disease”, and chronic wasting
disease of deer and elk [4]. In humans, prion
diseases occur in three distinct clinicopathological
entities [5]:
(i). Sporadic Creutzfeldt-Jakob disease (sCJD).
This is a rapidly progressive dementia, whose
etiology remains obscure.
(ii). Inherited human prion diseases. This family of
conditions is invariably linked to pathogenic
mutations in the gene encoding PrPC .
According to the presenting clinical syndrome
and the mutation, inherited human prion
diseases have been classified as familial
Creutzfeldt-Jakob disease (fCJD), Gerstmann-
I
*Address correspondence to this author at the nstitute of Neuropathology,
University Hospital of Zurich, Schmelzbergstrasse 12, CH-8091 Zurich,
Switzerland; Tel: +41 1 255 2107; Fax: +41 1 255 4402; E-mail:
markus.glatzel@usz.ch
Sträussler-Scheinker disease (GSS), and fatal
familial insomnia (FFI).
(iii). Acquired human prion diseases, due to
exposure to tissue, biologicals, or other
materials containing prions. Uptake of prions
can be due to medical procedures (iatrogenic
Creutzfeldt-Jakob disease, iCJD) or to
exposure of materials originating from cattle
a f f e c t e d  b y  b o v i n e  s p o n g i f o r m
encephalopathy (variant Creutzfeldt-Jakob
disease, vCJD). Kuru, which is caused by
cannibalism and may have been very common
in prehistory [6], is yet another example of
acquired human prion disease.
Prions can find their way through the body to the
brain of their host, and colonize various extracerebral
organs including the lymphoreticular system and
skeletal muscles. However histopathological changes
have not been identified in organs other than the
central nervous system (CNS). The process by which
prions travel through the body to the CNS is termed
neuroinvasion and comprises two phases [7]. A
primary phase of prion accumulation and replication
in organs of the lymphoreticular system (LRS) is
followed by a secondary phase which is initiated
once the agent has gained access to peripheral
nerves. It may be argued that this model
oversimplifies the complex mechanisms of prion
neuroinvasion, and indeed there are exceptions:
some studies have shown that prion neuroinvasion
along peripheral nerves can occur independently of
lymphoid prion replication [8], and not all lymphoid
organs are always colonized by prions [9]. However,
we maintain that the vast majority of experimental
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Figure 1. Accumulation of PrPSc in brains.
Histoblot showing PrPSc in a brain section of a mouse inoculated intranervally with prions. PrPSc accumulates selectively in
areas belonging to the sensory nervous system (thalamus).
data can be explained on the basis of the two-step
model of prion neuroinvasion.
PRIONS REPLICATE IN LYMPHOID ORGANS
The lymphoreticular system (LRS) is an early site
of prion replication. In experimental models of prion
diseases, PrPSc and prion-infectivity can be detected
in the LRS as early as five days following prion
challenge [10]. Which cell type is responsible for
replication and accumulation of prions in the LRS?
By separat ing stromal and non-stromal
compartments of the spleen, it was soon realized
that prion infectivity resides mainly in the stromal
compartment. Stromal cells such as follicular dendritic
cells (FDCs) were suspected to be the cell type
responsible for prion replication. Subsequently, a
number of studies strengthened this assumption. In
the 1980ies it could be shown that prion replication
in lymphoid organs is unaffected by whole-body
ionizing radiation, FDCs are known to be resistant to
ionizing radiation [11]. Further evidence that FDCs
accumulate PrPS c  came from investigations
demonstrating PrPSc accumulation on FDCs in
experimentally prion infected mice [12]. In addition,
intraperitoneal infection does not lead to replication
of prions in the spleen of mice with functionally
impaired FDCs [13]. Ultrastructural studies employing
immuno electron microscopy have shown that
disease-associated PrP (presumably identical to
PrPSc) is situated on the plasmalemma of FDCs [14].
Meanwhile it became obvious that the development
and maintenance of secondary lymphoid organs and
of FDCs is dependent on tumor necrosis factor,
lymphotoxin alpha, and lymphotoxin beta signaling
components [15]. Blocking of this pathway by
administration of a lymphotoxin beta receptor-
immunoglobulin fusion protein leads to the
disappearance of mature, functional FDCs and to a
significant reduction of prion infectivity in the spleen
[16, 17].
HOW DO PRIONS EXPLOIT PERIPHERAL
NERVES
Following intraperitoneal administration and
replication in organs of the LRS, it is believed that
prions gain access to peripheral nerves [7].
Considering the fact that PrPSc is localized on the
plasmalemma of FDCs, one could presume that
peripheral nerve entry occurs in the immediate
neighborhood of FDCs. Indeed studies looking at
the innervation pattern of lymphoid organs have
shown close vicinity of FDCs with nerve fibers [18].
How transport from cells belonging to the LRS to
peripheral nerves is accomplished is still a matter of
discussion. Access to peripheral nerves may be
facilitated if myelination of the nerves is reduced or
absent [19]. Considering this, the mantle zone of the
lymph follicles, which is innervated by terminal
unmyelinated nerve fibers, could be the entry point
of prions. A recently published study demonstrates
that relocalization of FDCs to highly innervated
regions within the LRS leads to accelerated prion
neuroinvasion. This provides further support of the
hypothesis that the distance between sites of prion
accumulation and nerve endings may control the
efficiency of neuroinvasion [20].
The possibility that prions may directly enter
peripheral nerves omitting the need for replication of
infectivity in lymphoid organs was raised by a study
showing neuroinvasion in mice in which PrPC
expression is limited to neuronal cells [8]. This
possibility was further highlighted by investigations
demonstrating direct prion neuroinvasion via a
defined nerve if prions are applied to corresponding
nerve endings [21].
HOW ARE PRIONS TRANSPORTED ALONG
PERIPHERAL NERVES?
Once invasion of the peripheral nervous system
(PNS) has taken place, the agent travels along
peripheral nerves to the CNS. There is substantial
evidence suggesting that prion transport in
peripheral nerves occurs in a PrPC dependent
fashion [7, 22, 23]. The exact mode of transport
within the PNS remains to be discovered: in principle
both axonal and non-axonal modes of transport are
conceivable. For PrPC transport in the fast axonal
pathway was shown [24]. For PrPSc the mode of
transport has been studied indirectly by comparing
the incubation times of mice inoculated in distal and
proximal portions of peripheral nerves or by
comparing incubation times of mice inoculated in
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Figure 2. Sympathetic innervation of lymphoreticular organs is rate limiting for prion neuroinvasion
Spinal cord histology showing pronounced gliosis in untreated (A) but not in sympathectomized (B) mice peripherally
challenged with prions. Sympathetic innervation of untreated (C) and sympathectomized (D) mouse spleens visualised by
anti-tyrosine hydroxylase immunostain.
peripheral nerves to mice that were inoculated
intracerebrally Figure 1 [19, 23]. The actual rate of
spread within the PNS was calculated to be around
1 to 2 mm/day. Obviously this rate of spread does
not correspond to the fast axonal transport. This
contention is supported by a study proving that prion
transport is unaltered in genetically modified mice
that harbour a defect in fast axonal transport [25].
The lack of experimental evidence for axonal modes
of prion transport in conjunction with several indirect
lines of evidence supporting non-axonal prion
transport led us to propose a “domino stone”
mechanism, by which incoming PrPSc converts
resident PrPC on the axolemmal surface, thereby
propagating spatially the infection [7]. Yet, until
experiments that provide us with an unambiguous
answer to this problem, such as direct visualization of
PrPSc transport in nerves, are nonexistent, this
mechanism remains purely hypothetical.
WHICH SUBSETS OF PERIPHERAL NERVES
TRANSPORT PRIONS?
The PNS is, like the immune system, made up of
several anatomically and functionally distinct
subcompartments. A part of the PNS is the
autonomous nervous system, which comprises the
sympathetic and parasympathetic nervous system,
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has been the focus of various studies on prion
neuroinvasion [26]. The first hints that prions might
invade the CNS using nerve fibers of the
autonomous nervous system came from studies
looking at pathological changes and prion replication
in various portions of the spinal cord [27]. This study
demonstrated that, following intraperitoneal
inoculation of prions, pathological changes typical of
prion diseases and prion replication first appear in
the mid thoracic spinal cord. Involvement of
sympathetic nerves was suggested due to the fact
that nerve fibers, belonging to the sympathetic
nervous system, enter the spinal cord at identical
sites. Direct evidence that sympathetic nerve fibers
seem to constitute the interface between organs of
the LRS and the CNS came from studies employing
various strategies of sympathectomy which lead to
impaired prion transport from lymphoid organs to the
CNS Figure 2  [28]. Conversely, transgenic mice
overexpressing nerve growth factor, whose spleens
are hyperinnervated, show accelerated prion
neuroinvasion [28]. The surprising finding that prion
infectivity titers seem to be elevated in
hyperinnervated spleens when compared to mice
with regular innervation patterns suggests that
sympathetic nerves, besides being involved in the
transport of prions, may also accumulate and
replicate prions in lymphatic organs [28, 29].
A recently published study, demonstrating PrPSc
in sympathetic ganglia of patients suffering from
vCJD, provides evidence that the model of
neuroinvasion established in genetically modified
mice might also apply to humans [30].
Further studies established the existence of an
additional access route to the CNS that bypasses
the spinal cord, using nerves of the parasympathetic
nervous system namely the vagal nerve [31]. This
alternative route via the vagal nerve seems to be of
paramount importance when animals are infected via
the oral route. On the other hand, PrPSc can also be
detected in sympathetic ganglia of animals infected
by the oral route.
CONCLUSIONS
Prion neuroinvasion proceeds by complex
mechanisms. It is quite remarkable that such
baroque pathways of spread have been developed
by an agent which – according to all available
evidence – consists exclusively of one single proteic
moiety. In order to reach the CNS, prions need intact
lymphoreticular compartments of the immune system,
and seem to replicate within germinal centers,
possibly within mature FDCs. Further transport is
provided by distinct subsets of peripheral nerves.
Although considerable progress has been made in
deciphering mechanisms underlying lymphoid prion
replication and prion transport along peripheral
nerves, numerous mechanisms await elucidation. A
non-exhaustive list of unresolved questions would
include the following:
- How are prion transferred from FDCs to nerve
endings? Are additional cell types other than
FDCs involved?
- How are prions transported within peripheral
nerves? Why is expression of PrPC required for
efficient prion transport?
- How does prion infectivity and/or PrPSc travel
across synapses?
Answering these questions will not be an easy
task, yet investigation of these subjects might yield
fundamental insights into the characteristics of these
novel and essentially mysterious agents, and may
yield useful leads for the diagnosis and therapy of
prion diseases.
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